Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Eledon Pharmaceuticals, Inc. | nvus-ex322_8.htm |
| EX-31.2 - EX-31.2 - Eledon Pharmaceuticals, Inc. | nvus-ex312_6.htm |
| EX-31.1 - EX-31.1 - Eledon Pharmaceuticals, Inc. | nvus-ex311_11.htm |
| EX-23.1 - EX-23.1 - Eledon Pharmaceuticals, Inc. | nvus-ex231_110.htm |
| EX-10.11 - EX-10.11 - Eledon Pharmaceuticals, Inc. | nvus-ex1011_319.htm |
| EX-10.10 - EX-10.10 - Eledon Pharmaceuticals, Inc. | nvus-ex1010_316.htm |
| EX-10.9 - EX-10.9 - Eledon Pharmaceuticals, Inc. | nvus-ex109_317.htm |
| EX-10.8 - EX-10.8 - Eledon Pharmaceuticals, Inc. | nvus-ex108_318.htm |
| EX-4.5 - EX-4.5 - Eledon Pharmaceuticals, Inc. | nvus-ex45_320.htm |
| EX-1.1 - EX-1.1 - Eledon Pharmaceuticals, Inc. | nvus-ex11_777.htm |
| 10-K - 10-K - Eledon Pharmaceuticals, Inc. | nvus-10k_20201231.htm |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Eledon Pharmaceuticals, Inc. (the “Company”) for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Gregory J. Flesher, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:
|
|
(1). |
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of |
|
|
(2). |
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: March 30, 2021 |
By: |
/s/ David-Alexandre C. Gros, M.D. |
|
|
|
David-Alexandre C. Gros, M.D. |
|
|
|
Chief Executive Officer (Principal Executive Officer) |